Showing results 1 to 2 of 2
| Title | Author(s) | Issue Date | |
|---|---|---|---|
KEYNOTE-122: Phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma Proceeding/Conference:Annals of Oncology | 2016 | ||
Pembrolizumab (MK-3475) vs Standard of Care Chemotherapy in Platinum Pretreated, Recurrent or Metastatic Nasopharyngeal Cancer: the Phase 2 Keynote-122 Study Proceeding/Conference:AHNS 9th International Conference of Head and Neck Cancer | 2016 |